

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 September 2020 (17.09.2020)



(10) International Publication Number
WO 2020/182927 A1

(51) International Patent Classification:

A61K 33/24 (2019.01) A61P 3/12 (2006.01)
A61K 31/78 (2006.01)

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(21) International Application Number:

PCT/EP2020/056595

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:

12 March 2020 (12.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/817,817 13 March 2019 (13.03.2019) US

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(71) Applicant: **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).

Published:

— with international search report (Art. 21(3))

(72) Inventors: **JONASSON, Jenny**; AstraZeneca AB, SE-151 85 Södertälje (SE). **GUZMAN, Nicolas**; AstraZeneca Pharmaceuticals LP, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(74) Agent: **STORM, Peter, Jan** et al.; AstraZeneca Intellectual Property, Milstein Building, Granta Park, Cambridge, Cambridgeshire CB21 6GH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: POTASSIUM-BINDING AGENTS FOR USE IN HEMODIALYSIS PATIENTS




Figure 1 Study flowchart

(57) Abstract: The present invention relates to the use of potassium-binding agents that are formulated to remove toxins, e.g., potassium ions, from the gastrointestinal tract at an elevated rate, without causing undesirable side effects, in hemodialysis patients. The compositions exhibit desired characteristics for the long term administration to treat or prevent the relapse or occurrence of certain conditions, for example hyperkalemia.